Eli Lilly completes its takeover of Dermira, Novartis and the NHS strike an ‘innovative’ cardiovascular deal, GSK’s CEO hopes to get six new drug approvals in the next year, and Aberdeen University’s Elasmogen announces it’s secured follow-on equity investment.
Interviews are usually quite intimidating situations, especially when you put increasing amounts of pressure on yourself to perform well. Whether the pressure is internal or external, it’s best to avoid some common interview mistakes that usually result from the nervous energy!
Turning 16 marks an important chapter for anyone, and for Star it’s no different. The first half of 2018 saw the appointment of a new Managing Director, some new faces in the leadership team, and a fresh rebrand to complement Star’s unrivalled offering to the healthcare industry.
Here at Star we’re working hard to recruit top talent for our clients and place fantastic people in roles they’ll love. If these longer evenings have got you thinking about changing roles, or you’re just curious about what’s out there, take a look at our top roles for August.
Star is delighted to announce that they have retained their Gold standard Investors In People accreditation. Investors In People (IIP), work with organisations globally who want to put the time and focus into their employees to develop them and help them reach their full potential.
We grabbed some time with Star Account Delivery Manager, Dan Everitt, to talk assessment centres, and just what it is that makes them so valuable for both candidates and clients.
Star is very proud to have been recognised by Great Place to Work® as one of the UK’s Best Workplaces for Women, including for equal numbers of men and women in teams, a flexible working policy, and more.
A market-leading outsourcing and resourcing provider that delivers award-winning quality services, Star are delighted to announce a new chapter in their journey, unveiling a new brand look that highlights their unrivalled offering to the healthcare industry.
Many of us recognise intellectually that we need others’ knowledge to address the opportunities and challenges we face in our day to day jobs in pharma, yet we still lack the time or motivation to collaborate. Engaging with third parties all too often feels inefficient.
Our world is changing. Over the last 15 years, 52% of Fortune 500 companies have disappeared. I often wonder if this trend will impact our sector. While pharma has been relatively isolated from disruptive technologies, the recently intensified pressure on drug pricing from policy makers is really challenging pharma executives.